Highlights WuXi Biologics (Cayman) Inc.

Equities

2269

KYG970081173

Delayed Hong Kong S.E. Other stock markets 02:47:40 2024-05-10 EDT			5-day change	1st Jan Change
14.62 ^HKD	+0.27%		+4.58%	-50.68%

04-01	Wuxi Biologics Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer	CI
03-27	WuXi Biologics' 2023 Profit Falls 23% Despite Revenue Jump	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pacific Assets Trust cautiously optimistic after outpacing benchmark	04-30	AN
WuXi Biologics' 2023 Profit Falls 23% Despite Revenue Jump	03-27	MT
WuXi Biologics 2023 Net Profit Fell on Higher Expenses, Impairment Losses	03-26	DJ
WuXi Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
WuXi AppTec's Shares Fall After Downbeat Guidance	03-19	DJ
WuXi AppTec's Net Profit Jumps, Reiterates It Doesn't Pose Security Threat	03-18	DJ
China stocks steady, helped by biotech rally; Wuxi Apptec drags Hong Kong shares	03-14	RE
Biotech trade association to split with China's WuXi AppTec	03-13	RE
WuXi Companies' Shares Rise on Receding Worries About Potential U.S. Sanctions	03-04	DJ
Wuxi Biologics Says It Is Not a Wuxi AppTec Subsidiary Amid US Security Risk Probe	02-13	MT
WuXi Companies' Shares Slide Amid Concerns Over Proposed U.S. Bill	02-02	DJ
WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland	01-31	CI
WuXi Biologics Launches WuXia ADCC PLUS? for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect	01-24	CI
WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody?	01-16	CI
Wuxi Biologics Shares Rise After Jump in December Projects	01-11	DJ
WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates	01-10	CI
Wuxi Biologics Announces to Increase Manufacturing Capacity in Massachusetts	01-08	CI
WuXi Biologics Inc. commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.	12-07	CI
WuXi Biologics Launches $600 Million Share Buyback Program	12-06	MT
Wuxi Biologics Sees Revenue Growing 10% in 2023	12-04	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights WuXi Biologics (Cayman) Inc.

Equities

2269

KYG970081173

Highlights

Filters